Iowa
Cancer clinical trials in Iowa
153 cancer studies are recruiting participants at sites in 18 cities across Iowa as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Iowa city with a recruiting study
By research area: Lymphoma (45), Breast Cancer (37), Lung Cancer (37), Prostate Cancer (16), Pancreatic Cancer (10), Melanoma (8).
Iowa City (91), Des Moines (62), Waukee (48), Clive (38), Ankeny (37), Cedar Rapids (37), Ames (35), Fort Dodge (31), Marshalltown (28), West Des Moines (16), Carroll (15), Bettendorf (9), Creston (8), Council Bluffs (6), Pella (6), Waterloo (5), Boone (4), Jefferson (4).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Breast cancer: recently updated in Iowa
Basic details from each study's public record (the 12 most recently updated of 153). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Recruiting in
- Iowa City
- Registry record
- NCT06324357 · updated
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Recruiting in
- Clive · Des Moines · West Des Moines
- Registry record
- NCT03418961 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Iowa on ClinicalTrials.gov.
Lung cancer: recently updated in Iowa
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Amgen
- Recruiting in
- Waterloo
- Registry record
- NCT05920356 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Iowa on ClinicalTrials.gov.
Prostate cancer: recently updated in Iowa
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Recruiting in
- Cedar Rapids
- Registry record
- NCT04423211 · updated
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Novartis Pharmaceuticals
- Recruiting in
- Iowa City
- Registry record
- NCT07190300 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Iowa on ClinicalTrials.gov.
Lymphoma: recently updated in Iowa
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Recruiting in
- Iowa City
- Registry record
- NCT06724237 · updated
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Waukee
- Registry record
- NCT06806033 · updated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Recruiting in
- Iowa City
- Registry record
- NCT07221500 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Iowa City · Waukee
- Registry record
- NCT06890884 · updated
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- AstraZeneca
- Recruiting in
- Iowa City
- Registry record
- NCT07109219 · updated
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Ankeny · Clive · Des Moines · and 1 more U.S. location
- Registry record
- NCT03739814 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Iowa on ClinicalTrials.gov.
Pancreatic cancer: recently updated in Iowa
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Phase 2
- Ages 12 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Iowa City
- Registry record
- NCT04924075 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Iowa on ClinicalTrials.gov.
Ask about studies in Iowa
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections